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Freeman: Letter from the Editor

Letter from the Editor

Paul B. Freeman, OD
Editor-in-Chief
“Just when you thought it was safe to go back in the water”
We are not yet out of the COVID pandemic, so I find myself beginning this
editorial with the pledge from my April 2021 editorial: “Until we have conquered
this pathogen, I will continue to recognize and thank, in each issue of our journal,
the frontline professionals and those workers who keep our lives moving forward
while putting themselves in harm’s way. My hope is that each time I begin with
this, it will be the last time.” 1 Unfortunately, there really doesn’t seem to be an end
in sight to the challenges we are going to face with respect to pandemic-related eye
and health issues, which are exacerbated by COVID fatigue (masking, social
distancing, psychological challenges, and all of the other limits on our lives), SARS
variants, seasonal COVID changes (like the flu), and now a new, potentially
emerging crisis: monkeypox virus. By the time this editorial is being read, I am
concerned that we could be in the midst of far more healthcare confusion than we
currently are in, regardless, I might add, of political persuasion. And, in addition to
the ophthalmic conditions caused by SARS-CoV2, we now must contend with the
ocular conditions that this newly circulating virus, “a member of the Orthopoxvirus
genus in the family Poxviridae,”2 will cause. So how do we prepare for this new
potential pandemic?
Fortunately(?), we have been well schooled in hygiene and protection from
respiratory droplets by using personal protective equipment (PPE) and plastic
shields, which we have become accustomed to since the onset of COVID-19.
Because one of the ways that monkeypox can be transmitted from person to person
is by respiratory droplets transmitted with prolonged face-to-face contact (think slit
lamp examination), or close contact with lesions, we may not be quite ready to let
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down our protective shields or casually dismiss the use of gloves. Perhaps like our
dental colleagues, eyecare providers should use masks for assessments or
procedures that require close or prolonged face- to- face time. Like all viruses, this
virus can lead to complaints of red, itching, or burning eyes, discharge, light
sensitivity, pain or discomfort, and/or blurred vision, which can result from
conjunctivitis, blepharitis, eye lid swelling, keratitis, corneal ulceration, and
scarring. Importantly, patients need to know that because they have these signs or
symptoms, that does not necessarily mean that they have monkeypox. With online
and social media information prevalent but not always accurate or complete, our
patients will rely on us for the best scientific information. Someone with
monkeypox will get a rash (the biggest “red flag”), but will also show symptoms of
fever, chills, swollen lymph nodes, exhaustion, muscle aches and backache,
headache, and respiratory symptoms such as sore throat, nasal congestion, or
coughing. 3 And while we are still suffering from what I am calling posttraumatic
virus disorder (PTVD), optometrists need to know that unlike the SARS-CoV2, the
monkeypox virus is self-limiting and tends to last 2 to 4 weeks, during which time,
because no specific treatment has been recommended, ophthalmic conditions
should be treated as one would treat any virus, with instructions to the patient
regarding hand washing and to avoid sharing anything that could transmit the virus
to another.
It seems that the bulk of the global population is at a low risk for monkeypox
infection but, as we have also heard on more than one occasion, “it ain’t rare if it’s
in your chair.” I suspect that some who are reading this editorial have already had
an opportunity to interact with someone with this virus or who was concerned that
their symptoms suggested they have the virus. I had this experience with a patient
who was concerned about a rash she had developed but had none of the other
symptoms. Both her husband and I talked her through the possible ways one could
get monkeypox, and we collectively decided that her rash was undoubtedly not due
to monkeypox. However, after seeing me, she also saw her primary care doctor who
assured her that she did not have this condition, a relief quite frankly, for me as
well. Finally, despite the fact that mortality is low with this disease, monkeypox
can be itchy or painful due to the rash.3
We are all familiar with treatments for both COVID-19, and now monkeypox. For
COVID-19, early on there were no definitive treatments, but we were all aware of
the importance for some needing respiratory care and hospitalization. Fortunately,
now there are 4 treatments for COVID-19 (specifically IV monoclonal antibody
bebtelovimab, and antivirals remdesivir, Paxlovid™, and molnupiravir4) and there
are vaccines which are designed to minimize the impact of COVID-19, just as flu
vaccines are designed to minimize the severe effects of influenza. For monkeypox,
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there is one specific vaccine (JYNNEOS®), and a vaccine developed for smallpox
(ACAM2000™) being used to prevent monkeypox infections.5 However, we
continue to have challenges with patients who have had multiple bouts of COVID
and we are now seeing patients who are suffering from long COVID.
In my low vision practice, the two biggest long-term effects of COVID that I have
seen are fatigue and brain fog, both of which can impact low vision patients,
possibly more so than someone with “normal” visual acuity. My concern for these
patients, especially given the advanced age of most, is whether the latter effect can
exacerbate the impact of decreased vision on cognition. A recent systematic review
and meta-analysis reported on the relationship between vision and cognition and
found “evidence for a direct link between visual impairment and cognitive
impairment, with visual impairment being associated with an approximately twofold increased odds of prevalent or incident cognitive impairment.”6 This is
undoubtedly due to visual impairments often limiting social and mentally
stimulating activities, and that was before considering the issue of brain fog from
COVID; now, add brain fog, which can be described as “difficulty thinking or
concentrating.”7 Please note that I’m not suggesting low vision rehabilitation is the
answer to brain fog, but actively stimulating cognition by using low vision
rehabilitative management techniques may mitigate the impact of brain fog when
combined with the impact of vision loss on cognition. Helping these patients engage
with mentally stimulating activities (especially as one gets older) like reading
books, playing games, computer use, and getting involved in social activities can
minimize mild cognitive impairment, a potential precursor to more severe cognitive
difficulties,8 and can be accomplished with low vision rehabilitation management.
So where do we go from here? I am reminded of the recent increase in shark
attacks in the United States, some only a few hours apart, as was the case in South
Carolina this August. Swimmers were reminded not to swim at dawn or dusk, not
to swim where there are schools of small fish, or where people are fishing. Despite
that, one of the shark attacks happened when the victim was only waist deep in
water, and not in any of the situations that were warned against.9 Warnings and
consequences sound familiar? So, as swimmers are reminded when it’s safe to go
back into the water, they must still be vigilant and aware of the consequences of
their actions even under ideal conditions. As the COVID restrictions placed on us
are loosened and we feel it is safe to go back into the “viral” water, we must also
be aware of consequences, even under ideal conditions. As optometrists, we are
part of the public health care team, and we each should decide how much precaution
we are going to take individually, in our practices, and when counseling our
patients, because just when we think it is safe to go back into the water…
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